260 related articles for article (PubMed ID: 22560300)
1. GPR119 as a fat sensor.
Hansen HS; Rosenkilde MM; Holst JJ; Schwartz TW
Trends Pharmacol Sci; 2012 Jul; 33(7):374-81. PubMed ID: 22560300
[TBL] [Abstract][Full Text] [Related]
2. 2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans.
Hansen KB; Rosenkilde MM; Knop FK; Wellner N; Diep TA; Rehfeld JF; Andersen UB; Holst JJ; Hansen HS
J Clin Endocrinol Metab; 2011 Sep; 96(9):E1409-17. PubMed ID: 21778222
[TBL] [Abstract][Full Text] [Related]
3. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic potential of GPR119 agonists for type 2 diabetes.
Ohishi T; Yoshida S
Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451
[TBL] [Abstract][Full Text] [Related]
5. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders.
Shah U; Kowalski TJ
Vitam Horm; 2010; 84():415-48. PubMed ID: 21094910
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119.
Wacker DA; Wang Y; Broekema M; Rossi K; O'Connor S; Hong Z; Wu G; Malmstrom SE; Hung CP; LaMarre L; Chimalakonda A; Zhang L; Xin L; Cai H; Chu C; Boehm S; Zalaznick J; Ponticiello R; Sereda L; Han SP; Zebo R; Zinker B; Luk CE; Wong R; Everlof G; Li YX; Wu CK; Lee M; Griffen S; Miller KJ; Krupinski J; Robl JA
J Med Chem; 2014 Sep; 57(18):7499-508. PubMed ID: 25208139
[TBL] [Abstract][Full Text] [Related]
7. Bidirectional GPR119 Agonism Requires Peptide YY and Glucose for Activity in Mouse and Human Colon Mucosa.
Tough IR; Forbes S; Herzog H; Jones RM; Schwartz TW; Cox HM
Endocrinology; 2018 Apr; 159(4):1704-1717. PubMed ID: 29471473
[TBL] [Abstract][Full Text] [Related]
8. GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders.
Shah U
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):519-32. PubMed ID: 19562648
[TBL] [Abstract][Full Text] [Related]
9. [GPR119 Receptor Agonists: Characteristics, Physiological Role, Prospects of Use in the Treatment of Diabetes Mellitus Type 2 and Metabolic Syndrome].
Tyurenkov IN; Kurkin DV; Bakulin DA; Lomkina EM; Volotova EV
Usp Fiziol Nauk; 2015; 46(4):28-37. PubMed ID: 27183782
[TBL] [Abstract][Full Text] [Related]
10. GPR119 agonists for the treatment of type 2 diabetes.
Jones RM; Leonard JN; Buzard DJ; Lehmann J
Expert Opin Ther Pat; 2009 Oct; 19(10):1339-59. PubMed ID: 19780700
[TBL] [Abstract][Full Text] [Related]
11. Targeting GPR119 for the potential treatment of type 2 diabetes mellitus.
Mo XL; Yang Z; Tao YX
Prog Mol Biol Transl Sci; 2014; 121():95-131. PubMed ID: 24373236
[TBL] [Abstract][Full Text] [Related]
12. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity.
Overton HA; Fyfe MC; Reynet C
Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S76-81. PubMed ID: 18037923
[TBL] [Abstract][Full Text] [Related]
13. Oleoyl-lysophosphatidylinositol enhances glucagon-like peptide-1 secretion from enteroendocrine L-cells through GPR119.
Arifin SA; Paternoster S; Carlessi R; Casari I; Ekberg JH; Maffucci T; Newsholme P; Rosenkilde MM; Falasca M
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Sep; 1863(9):1132-1141. PubMed ID: 29883799
[TBL] [Abstract][Full Text] [Related]
14. Biased signaling of lipids and allosteric actions of synthetic molecules for GPR119.
Hassing HA; Fares S; Larsen O; Pad H; Hauge M; Jones RM; Schwartz TW; Hansen HS; Rosenkilde MM
Biochem Pharmacol; 2016 Nov; 119():66-75. PubMed ID: 27569424
[TBL] [Abstract][Full Text] [Related]
15. Identification of Novel, Structurally Diverse, Small Molecule Modulators of GPR119.
Nieto A; Fernández-Vega V; Spicer TP; Sturchler E; Adhikari P; Kennedy N; Mandat S; Chase P; Scampavia L; Bannister T; Hodder P; McDonald PH
Assay Drug Dev Technol; 2018 Jul; 16(5):278-288. PubMed ID: 30019946
[TBL] [Abstract][Full Text] [Related]
16. GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis.
Lan H; Vassileva G; Corona A; Liu L; Baker H; Golovko A; Abbondanzo SJ; Hu W; Yang S; Ning Y; Del Vecchio RA; Poulet F; Laverty M; Gustafson EL; Hedrick JA; Kowalski TJ
J Endocrinol; 2009 May; 201(2):219-30. PubMed ID: 19282326
[TBL] [Abstract][Full Text] [Related]
17. Regulation of GPR119 receptor activity with endocannabinoid-like lipids.
Syed SK; Bui HH; Beavers LS; Farb TB; Ficorilli J; Chesterfield AK; Kuo MS; Bokvist K; Barrett DG; Efanov AM
Am J Physiol Endocrinol Metab; 2012 Dec; 303(12):E1469-78. PubMed ID: 23074242
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for constitutive activity and agonist-induced activation of the enteroendocrine fat sensor GPR119.
Engelstoft MS; Norn C; Hauge M; Holliday ND; Elster L; Lehmann J; Jones RM; Frimurer TM; Schwartz TW
Br J Pharmacol; 2014 Dec; 171(24):5774-89. PubMed ID: 25117266
[TBL] [Abstract][Full Text] [Related]
19. Oral 2-oleyl glyceryl ether improves glucose tolerance in mice through the GPR119 receptor.
Hassing HA; Engelstoft MS; Sichlau RM; Madsen AN; Rehfeld JF; Pedersen J; Jones RM; Holst JJ; Schwartz TW; Rosenkilde MM; Hansen HS
Biofactors; 2016 Nov; 42(6):665-673. PubMed ID: 27297962
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile.
Semple G; Lehmann J; Wong A; Ren A; Bruce M; Shin YJ; Sage CR; Morgan M; Chen WC; Sebring K; Chu ZL; Leonard JN; Al-Shamma H; Grottick AJ; Du F; Liang Y; Demarest K; Jones RM
Bioorg Med Chem Lett; 2012 Feb; 22(4):1750-5. PubMed ID: 22264481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
